Wegovy Users Face 5x Higher Risk of Permanent Sight Loss, Study Finds
A landmark study has found that users of Wegovy and similar GLP-1 receptor agonists face approximately five times the risk of developing NAION, a condition that causes sudden, permanent vision loss. With over 37 million GLP-1 prescriptions written, understanding personal risk factors is critical.
About This Calculator: Wegovy NAION Risk
Why: This calculator helps current or prospective Wegovy/Ozempic users understand their individual NAION risk based on age and comorbidities, so they can have informed conversations with their doctor.
How: Enter your age, BMI, health conditions, and planned usage duration. The calculator applies the study's 5x multiplier and comorbidity factors to estimate your risk profile.
Try a Scenario:
Risk Factor Contribution Breakdown
Multipliers from each risk factor affecting your NAION risk.
Risk Composition
Baseline vs GLP-1 added risk vs comorbidity risk.
Risk Over Time
Cumulative NAION risk by month of usage.
Benefit vs Risk Comparison
Weight loss benefit score vs eye risk score.
⚠️For educational and informational purposes only. Verify with a qualified professional.
A landmark study published in JAMA Ophthalmology has found that users of Wegovy and similar GLP-1 receptor agonists face approximately five times the risk of developing NAION (non-arteritic anterior ischemic optic neuropathy), a condition that causes sudden, permanent vision loss. With over 37 million GLP-1 prescriptions written globally, understanding your personal risk profile is critical. NAION affects an estimated 2-10 per 100,000 people annually in the general population; the study suggests this baseline risk is multiplied by GLP-1 use and further elevated by age and comorbidities.
Sources: JAMA Ophthalmology, NHS, FDA adverse event reports.
Key Takeaways
- • GLP-1 receptor agonists (Wegovy, Ozempic) are associated with approximately 5x higher NAION risk compared to non-users, per the JAMA Ophthalmology study.
- • Age over 50 (especially over 60), hypertension, diabetes, and sleep apnea compound the risk. Multiple factors increase your individual risk profile.
- • NAION causes sudden, painless vision loss in one eye, often upon waking. Vision loss is typically permanent. Seek immediate ophthalmologic care if you notice changes.
- • The absolute risk remains low for most users. Do not stop medication without consulting your doctor; discuss screening and monitoring if you have risk factors.
Did You Know?
How Does the Risk Calculation Work?
Baseline and GLP-1 Multiplier
We use a baseline NAION incidence of 2 per 100,000 (0.002%) and apply the study's 5x GLP-1 multiplier. This gives a base elevated risk for any GLP-1 user.'
Age and Comorbidity Factors
Age over 50 adds a 1.5x multiplier; over 60 adds 2.0x. Hypertension (1.4x), diabetes (1.3x), and sleep apnea (1.5x) further increase risk based on known NAION risk factors.
Duration Adjustment
Longer planned usage increases cumulative exposure. We scale risk by (months / 12) to approximate duration-adjusted risk over your treatment period.
Expert Tips
Risk Factor Impact Summary
| Factor | Multiplier | Notes |
|---|---|---|
| GLP-1 use | 5.0x | JAMA study finding |
| Age 50-59 | 1.5x | NAION more common in older adults |
| Age 60+ | 2.0x | Highest age risk |
| Hypertension | 1.4x | Vascular risk factor |
| Diabetes | 1.3x | Microvascular effects |
| Sleep apnea | 1.5x | Oxygen desaturation, vascular stress |
Frequently Asked Questions
What is NAION?
NAION (non-arteritic anterior ischemic optic neuropathy) is sudden, painless vision loss in one eye caused by reduced blood flow to the optic nerve. It typically occurs upon waking and affects 2-10 per 100,000 people annually. Vision loss is often permanent.
How much does Wegovy increase NAION risk?
A 2024 study published in JAMA Ophthalmology found that users of semaglutide (Wegovy, Ozempic) face approximately 5x higher risk of NAION compared to non-users. The absolute risk remains low but increases with age and comorbidities.
What are the symptoms of NAION?
NAION typically presents as sudden, painless vision loss in one eye, often noticed upon waking. Visual field defects (especially altitudinal) and reduced color perception may occur. Seek immediate ophthalmologic care if you experience sudden vision changes.
Should I stop taking Wegovy?
Do not stop or change your medication without consulting your doctor. The absolute NAION risk remains low (roughly 2-10 per 100,000 baseline, increased ~5x with GLP-1 use). Your physician can weigh benefits (weight loss, diabetes control) against individual risk factors.
Who is at highest risk for NAION with GLP-1 drugs?
Higher risk factors include age over 50 (especially over 60), hypertension, diabetes, and sleep apnea. The JAMA study identified these as compounding factors. Discuss screening and monitoring with your ophthalmologist if you have multiple risk factors.
Is Ozempic affected too?
Yes. Ozempic and Wegovy share the same active ingredient (semaglutide). Ozempic is the diabetes formulation; Wegovy is the weight-loss formulation. The study findings apply to both, as the mechanism is linked to the GLP-1 receptor agonist class.
Key Statistics
- • 2-10 per 100,000: Annual NAION incidence in general population
- • 5x: Approximate risk increase for GLP-1 users (JAMA Ophthalmology)
- • 37M+: Global GLP-1 prescriptions (Wegovy, Ozempic, others)
- • 50+: Age at which NAION incidence rises significantly
- • One eye: NAION typically affects one eye; second-eye involvement is rare
Official Data Sources
- JAMA Ophthalmology — Peer-reviewed study on GLP-1 and NAION
- NHS Medicines Information — Semaglutide (Wegovy) prescribing guidance
- FDA Drug Safety — Adverse event reporting and safety communications
- American Academy of Ophthalmology — NAION patient information and clinical guidelines
Medical Disclaimer
This calculator is for educational and informational purposes only and does not constitute medical advice. The risk estimates are based on published research and simplified models; they are not a substitute for professional medical evaluation. Individual risk varies and depends on many factors not captured here. Do not start, stop, or change any medication based on this tool. Always consult your doctor or qualified healthcare provider for personalized advice. If you experience sudden vision loss or changes, seek immediate ophthalmologic care. The creators of this calculator are not responsible for any medical decisions made based on its output.